ArticleMini reviews in medicinal chemistry2026
Polymer-doxorubicin Conjugates: Redefining Chemotherapy for Breast Cancer.
Article in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymer drug conjugates (PDCs) represent a targeted modification of conventional chemotherapeutics, transforming small-molecule drugs like doxorubicin (dox) into macromolecular structures with significantly altered biological properties. By incorporating a biocompatible polymer backbone, a cleavable linker, and an active cytotoxic payload, PDCs achieve prolonged systemic persistence, advantageous biodistribution, and tumor-specific release. This architecture facilitates more reliable exploitation of the enhanced permeability and retention (EPR) effect, thereby encouraging preferential intratumoral accumulation while reducing off-target exposure. The regulated and microenvironment-sensitive release of dox provides a logical approach to mitigate cardiotoxicity, a significant limitation of anthracycline treatment. PDCs can partially bypass efflux-mediated multidrug resistance by using endocytic uptake pathways rather than transporter-dependent mechanisms. Prototypical systems such as HPMA-dox and PEG-dox offer persuasive translational evidence that macromolecular conjugation can enhance the therapeutic index of dox. PDCs collectively demonstrate how advanced molecular engineering might rejuvenate traditional chemotherapeutics for contemporary oncology.
Indexed as
Identifiers
42051094What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.